Pricing Log in Create free account

ArriVent BioPharma, Inc. (AVBP) vs Monte Rosa Therapeutics, Inc. (GLUE)

ArriVent BioPharma, Inc. and Monte Rosa Therapeutics, Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Monte Rosa Therapeutics, Inc. are of similar size ($863.4M and $827.9M). ArriVent BioPharma, Inc. has the higher net margin (0.00% vs −560.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Monte Rosa Therapeutics, Inc. leads on 6 and ArriVent BioPharma, Inc. on 5.

Valuation

Metric AVBP GLUE Biotechnology median
P/E n/m n/m 8.50
P/S n/m 34.41 9.71
P/B 2.16 2.03 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 12.79 9.21
Earnings yield (21.73%) (18.07%) (33.15%)
Free cash flow yield (18.65%) (3.25%) (25.50%)

Profitability

Metric AVBP GLUE Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (633.04%) 0.00%
Net margin 0.00% (560.85%) 0.00%
Free cash flow margin 0.00% (111.66%) 0.00%
Return on equity (53.10%) (42.66%) (56.36%)
Return on assets (49.30%) (30.67%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP GLUE Biotechnology median
Revenue growth (TTM) — (83.86%) 6.02%
EPS growth (last fiscal year) (68.75%) 53.06% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVBP GLUE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.16 10.58 4.72
Net debt to EBITDA 1.73 8.22 0.96

Dividend

Metric AVBP GLUE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AVBP GLUE Biotechnology median
Market cap 827.88m 863.37m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack